HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 23.19% from the stock’s current price.

GMAB has been the subject of a number of other research reports. New Street Research set a $43.00 price objective on shares of Genmab A/S in a report on Wednesday, July 22nd. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. Guggenheim boosted their price target on Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 7th. Truist Financial assumed coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and lifted their target price for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $39.50.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $32.47 on Monday. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $35.43. The business has a 50 day simple moving average of $31.00 and a two-hundred day simple moving average of $28.26. The firm has a market capitalization of $20.25 billion, a PE ratio of 25.57, a price-to-earnings-growth ratio of 1.83 and a beta of 0.84. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. On average, equities analysts predict that Genmab A/S will post 1.17 EPS for the current year.

Institutional Trading of Genmab A/S

Institutional investors have recently modified their holdings of the company. Paradigm Biocapital Advisors LP acquired a new position in shares of Genmab A/S during the third quarter worth $117,063,000. Orbis Allan Gray Ltd increased its position in Genmab A/S by 30.2% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after buying an additional 3,340,456 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after buying an additional 1,334,919 shares during the last quarter. First Trust Advisors LP boosted its holdings in Genmab A/S by 84.3% in the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after acquiring an additional 1,126,069 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after acquiring an additional 921,700 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.